After 18 years in charge, BioMarin Pharma’s chief executive and chairman, Jean-Jacques Bienaimé, has announced his retirement, with a high-powered replacement already lined up. Genentech CEO ...

The layoffs, he said, are part of the company’s ongoing shift. Former Genentech CEO Alexander Hardy took over BioMarin’s top ...

BioMarin's chief executive Alexander Hardy – who took the helm of the company after the departure of former CEO Jean-Jacques Bienaimé last December – described Friberg as "a world-class ...

An 08/2024 article discussed BioMarin's plans to better the situation, noting that CEO Hardy indicated he might sell the drug if its efforts aare unsuccessful. BioMarin's financial outlook builds ...

However, under the leadership of CEO Alexander Hardy ... A significant part of BioMarin’s growth strategy involves Voxzogo, which has shown strong sales performance. Although facing competition ...

SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for ...

Citi analyst David Lebowitz maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of $81.00. Discover outperforming stocks and invest ...